Halo Pharma is providing its pharmaceutical manufacturing partners the technical expertise and advanced formulation technology to support the development and manufacturing of fixed-dose combination (FDC) drugs, a rapidly growing market niche, according to the company.

FDC drugs combine multiple active pharmaceutical ingredients (APIs) into a single-dose product, which the company says helps improve patient convenience and the likelihood for medication compliance and appropriate dosing. In addition, the contract development and manufacturing organization (CDMO) says pharma companies can realize savings when developing an FDC comprised of previously approved new chemical entities or their generic counterparts. In addition, bringing to market a FDC product can extend the market potential of proprietary drugs.

Halo’s FDC formulation capabilities include hot melt extrusion, wet granulation/roller compaction, extrusion-spheronization, and fluid bed technology, as well as multiparticulate capsule filling and bilayer press capabilities. The company says the flexibility and variety of manufacturing platforms it offers allows customers to choose the FDC solid dosage form that is the most suitable for their clinical needs.

“We have seen a marked interest in FDC products from current and new customers,” said says Lee Karras, chief executive officer, Halo Pharma. “The capabilities Halo possesses, all under one roof, provide many options for our customers in the development of their products. Halo is one of very few CDMOs who have development and commercial manufacturing experience in FDCs. We have made and will continue to make significant investments in equipment and technical expertise at Halo to support this platform.”

To learn more about Halo Pharma’s FDC specialty products and capabilities visit www.halopharma.com/combo.